Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Raymond James Upgrades Andrx to 'Strong Buy'

Raymond James upgraded Andrx (ADRX) to strong buy from market perform.

On Friday Andrx settled a patent dispute with Pfizer and Alza Corp. over diabetes drug Glucotrol XL. Analyst Michael Krensavage tied his upgrade to a pact that should allow Andrx to launch a generic version of Glucotrol XL, which he thinks will reach the market in January. Also, he upgraded on the assumption that Andrx will start getting contribution from its generic version of antidepressant Wellbutrin SR early in 2004.

Krensavage upped the 75 cents 2004 earnings per share estimate to $1.21, which assumes 68 cents earnings per share from these two drugs, offset partly by an expected rise in competition for the generic version of Prilosec, from which Andrx receives royalties.

blog comments powered by Disqus